Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Adductor Canal Block for Outpatient TKA Recovery
NCT03038425Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- May 2017
- Primary completion
- Apr 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in pain (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Quality of Recovery Scale 15 at 1 day. Started May 2017; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
pain
Beyond the preview
Go deeper on NCT03038425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038425.